Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals.

A new test can genetically ‘barcode’ bowel cancer and separate it into five different diseases that could each receive tailored treatment, a new study reports.

Researchers at the ICR show that triple drug combinations could prevent resistance in many cancer types.